http://www.fpnotebook.com/
LamivudineAka: 3TC
- Mechanism
- Efficacy
- Very effective in combination with Zidovudine (AZT)
- Adverse Effects
- Generally Well tolerated
- Similar to Zidovudine (AZT) but much less severe
- Gastrointestinal upset
- Neutropenia
- Dosing
- Lamivudine 150 mg bid ($224/month)
Lamivudine (C0209738) | |
|---|---|
| Definition (CSP) | zalcitabine analog |
| Definition (MSH) | A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| Definition (NCI) | A drug used to treat infection caused by viruses. |
| Definition (PDQ) | A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1471" NCI Thesaurus) |
| Definition (NCI) | A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04) |
| Concepts | Nucleic Acid, Nucleoside, or Nucleotide (T114) , Pharmacologic Substance (T121) |
| MSH | D019259 |
| English | 2'3' dideoxy 3' thiacytidine, 3TC, DIDEOXYTHIACYTIDINE 002 003 003, Lamivudine, LAMIVUDINE PREPARATION, THREE TC |
| Spanish | lamivudina |
| Parent Concepts | 2',3'-Dideoxynucleosides (C0282384), Zalcitabine (C0012132), Reverse Transcriptase Inhibitors (C0282519), Antiviral Agents (C0003451), Drug allergen (C1320237), Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (C1579421) |
| Sources | CSP, LNC, MSH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
